Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines

Area of Science:

• Oncology
• Immunology
• Nanotechnology

Background:

• Cancer remains a leading cause of death, necessitating safer and more effective therapies.
• Neoantigen-based cancer vaccines show promise for immune responses, but tumour immunosuppression is a major hurdle.
• Advances in glycomics reveal cancer-specific glycosignatures with potential for glycovaccines.

Purpose of the Study:

• To provide a comprehensive overview of emerging cancer glycovaccines.
• To emphasize the potential of nanotechnology in developing effective cancer glycovaccines.
• To outline a roadmap for the clinical implementation of glycan-based cancer immunotherapies.

Main Methods:

• Reviewing strategies to overcome tumour immunosuppression, including glycan modification and adjuvant use.
• Exploring novel vaccine vehicles, particularly nanovehicles, for enhanced antigen delivery and immune cell targeting.
• Investigating glycan designs that exploit antigen-presenting cell (APC) recognition for improved payload delivery.

Main Results:

• Nanovehicles demonstrate increased affinity for APCs in lymph nodes and tumours, reducing toxicity.
• Exploiting APC-recognized glycans enhances antigenic payload delivery, boosting innate and acquired immune responses.
• These approaches show potential for reducing tumour burden and establishing long-term immunological memory.

Conclusions:

• Emerging cancer glycovaccines, particularly those utilizing nanotechnology, offer a promising strategy to combat cancer.
• Nanotechnology enhances glycovaccine delivery and efficacy by improving APC targeting and payload delivery.
• Further development and clinical implementation of these glycan-based strategies are crucial for advancing cancer immunotherapy.